PD DETECT<\/b> offers decisive advantages for the diagnosis of neurodegenerative diseases<\/p>\n<\/div>- <\/i><\/span>
\n
Early detection:<\/b> identification of SAA-positive patients at an early stage of the disease <\/p>\n<\/div><\/li><\/ul>- <\/i><\/span>
\n
Precision:<\/b> <\/span>High sensitivity and specificity enable a clear differential diagnosis between Parkinson’s and MSA<\/p>\n<\/div><\/li><\/ul>- <\/i><\/span>
Qualitative:<\/span> <\/b>Yes\/no result within 15 business days<\/div><\/li><\/ul>- <\/i><\/span>
Quantitative:<\/b> Determination of the LFP score for seed load quantification<\/div><\/li><\/ul><\/div><\/div><\/div><\/div>![\"Dr.](\"https:\/\/www.modag.net\/wp-content\/uploads\/2024\/12\/27595935.jpg\" "\\"27595935\\"")
<\/span><\/div><\/div><\/div><\/i>This test represents a significant advance in Parkinson’s diagnostics<\/span> by <\/span> enabling early and accurate detection of the disease<\/span>, which could be of great importance for future treatment strategies.”<\/h3><\/div><\/div>
Dr. Torsten Matthias, CEO<\/h4><\/div><\/div><\/div><\/div><\/div>PD DETECT in comparison <\/span>
Diagnostic procedures using the example of Parkinson’s disease<\/span>
<\/span><\/span><\/h2><\/div><\/div><\/div>Clinical examination
<\/h3><\/div>Traditional: <\/b><\/p>\n
Diagnosis based on symptoms such as tremor, muscle stiffness and slowed movements in combination with neuroimaging techniques<\/p>\n<\/div><\/div><\/div>
PD DETECT:<\/b><\/p>\n
Can detect Parkinson\u2019s disease even at an early stage of the disease<\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div>
Imaging procedures
<\/h3><\/div>Traditional:<\/b><\/p>\n
Show structural changes or dopamine deficiency in the brain<\/p>\n<\/div><\/div><\/div>
PD DETECT:<\/b><\/p>\n
Directly detects misfolded alpha-synuclein proteins that are causative for Parkinson’s disease<\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div>
L-Dopa test<\/h3><\/div><\/div><\/div><\/div>
Traditional:<\/b><\/p>\n
Tests the response to Parkinson’s medication<\/p>\n<\/div><\/div><\/div>
PD DETECT:<\/b><\/p>\n
Enables a diagnosis regardless of the response to medication<\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>
<\/div>
Application examples and clinical relevance<\/h3><\/div>PD DETECT offers a wide range of applications in clinical practice<\/p>\n
1. objective diagnosis: <\/b>
<\/span>Thanks to its high sensitivity, PD DETECT can detect alpha-synuclein pathologies at an early stage of the disease. PD DETECT supports doctors in making a diagnosis more quickly and thus reduces the time patients have to wait for a diagnosis. <\/p>\n2. differential diagnosis:<\/b><\/span>
With a specificity of 100% in differentiating between Parkinson’s and MSA, PD DETECT supports physicians in making a precise diagnosis. This is particularly important as the treatment approaches for these diseases differ. <\/p>\n3. therapy monitoring:<\/b><\/span>
The quantitative LFP score makes it possible to objectively assess the course of the disease and the effectiveness of therapies.<\/p>\n4. research:<\/b><\/span>
PD DETECT can be used in clinical trials to evaluate the efficacy of new therapies and deepen our understanding of disease mechanisms.<\/p>\nThe clinical relevance of PD DETECT lies in the improvement of patient care through more precise diagnoses, early intervention options and individualized treatment strategies.<\/p>\n<\/div><\/div><\/div><\/div><\/div>
Future prospects<\/h3><\/div>The development of PD DETECT opens up exciting possibilities for the future of Parkinson’s diagnosis and treatment<\/p>\n<\/div>
- <\/i><\/span>
Screening programs:<\/b><\/span> In the long term, PD DETECT could be used in screening programs for at-risk groups to detect Parkinson’s in its early stages.<\/span><\/div><\/li>- <\/i><\/span>
Personalized medicine:<\/b> <\/span>Quantitative analysis could contribute to the development of customized therapies tailored to a patient’s individual disease profile.<\/span><\/div><\/li>- <\/i><\/span>
Biomarker-supported therapy development:<\/b><\/span> PD DETECT could accelerate the development of new drugs by enabling precise measurements of alpha-synuclein pathology in clinical trials.<\/span><\/div><\/li>- <\/i><\/span>
Integration with other biomarkers:<\/b><\/span> In the future, PD DETECT could be combined with other biomarkers to obtain an even more comprehensive picture of the disease state.<\/span><\/div><\/li>- <\/i><\/span>
\n
Extension to other neurodegenerative diseases:<\/b><\/span> The technology behind PD DETECT could be adapted for the diagnosis of other proteinopathies.<\/span><\/p>\n<\/div><\/li><\/ul><\/div><\/div><\/div><\/div>![\"Paar](\"https:\/\/www.modag.net\/wp-content\/uploads\/2025\/01\/Paar-mit-Decke-1x1-1.webp\" "\\"Paar")
<\/span><\/div><\/div><\/div>At MODAG, we are continuously working on further developing PD DETECT<\/span> and optimizing its use in clinical practice.<\/h3><\/div>Our aim is to fundamentally improve the diagnosis and treatment of Parkinson’s and related diseases and thus sustainably improve the quality of life of those affected.<\/p>\n<\/div>
<\/div><\/div><\/div><\/div><\/div>